Programmed death ligand 1 (PD-L1) status and tumor-infiltrating lymphocytes in hot spots of primary and liver metastases in prostate cancer with neuroendocrine differentiation
Background - Prostate cancer with neuroendocrine differentiation (NEPCA) shares similarities in tumor biology with small-cell lung cancer. While immunotherapies were successfully tested in small-cell lung cancer, and programmed death ligand 1 (PD-L1) expression arises as an essential predictive biom...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2019
|
| In: |
Clinical genitourinary cancer
Year: 2018, Volume: 17, Issue: 2, Pages: 145-153.e5 |
| ISSN: | 1938-0682 |
| DOI: | 10.1016/j.clgc.2018.12.007 |
| Online Access: | Verlag, Volltext: https://doi.org/10.1016/j.clgc.2018.12.007 Verlag, Volltext: http://www.sciencedirect.com/science/article/pii/S1558767318305895 
|
| Author Notes: | Jost von Hardenberg, Sarah Hartmann, Katja Nitschke, Thomas Stefan Worst, Saskia Ting, Henning Reis, Philipp Nuhn, Cleo-Aron Weis, Philipp Erben |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1662886128 | ||
| 003 | DE-627 | ||
| 005 | 20240323101131.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 190405r20192018xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.clgc.2018.12.007 |2 doi | |
| 035 | |a (DE-627)1662886128 | ||
| 035 | |a (DE-599)KXP1662886128 | ||
| 035 | |a (OCoLC)1341205999 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Hardenberg, Jost von |d 1982- |e VerfasserIn |0 (DE-588)1020494328 |0 (DE-627)688149278 |0 (DE-576)360578241 |4 aut | |
| 245 | 1 | 0 | |a Programmed death ligand 1 (PD-L1) status and tumor-infiltrating lymphocytes in hot spots of primary and liver metastases in prostate cancer with neuroendocrine differentiation |c Jost von Hardenberg, Sarah Hartmann, Katja Nitschke, Thomas Stefan Worst, Saskia Ting, Henning Reis, Philipp Nuhn, Cleo-Aron Weis, Philipp Erben |
| 264 | 1 | |c 2019 | |
| 300 | |a 14 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Available online 21 December 2018 | ||
| 500 | |a Gesehen am 22.05.2019 | ||
| 520 | |a Background - Prostate cancer with neuroendocrine differentiation (NEPCA) shares similarities in tumor biology with small-cell lung cancer. While immunotherapies were successfully tested in small-cell lung cancer, and programmed death ligand 1 (PD-L1) expression arises as an essential predictive biomarker, the local immune status in NEPCA is still poorly described. - Patients and Methods - Paraffin-embedded tissue samples of 39 patients (7 adenocarcinomas with neuroendocrine differentiation [ACA NED], 20 small-cell neuroendocrine carcinomas, 2 well-differentiated neuroendocrine tumors of NEPCA, and 10 adenocarcinoma liver metastases) were examined retrospectively by immunohistochemistry of chromogranin A (CGA), CD56, synaptophysin (SYN), CD3, and PD-L1. Laser capture microdissection was used for neuroendocrine hot-spot evaluation for additional real-time reverse transcription-quantitative PCR analysis (PD-L1, CGA, CD56, SYN, GRP, ASCL1, and DLK1). - Results - PD-L1 immunohistochemistry expression in NEPCA was observed by assay E1L3N in 5 (20.8%) of 24 samples, but not by assay 22c3. Gene expression of PD-L1 could be evaluated in 18 (62%) of 29 samples. Nine (69%) of 13 prostate specimens and 2 (40%) of 5 liver metastases were positive for PD-L1. In ACA NED 4 (80%) of 5 and in small-cell neuroendocrine carcinomas 6 (50%) of 12 specimens were positive for PD-L1. Tumor-infiltrating lymphocytes ≥ 10% were observed in 9 (37.5%) of 24 specimens. Low ASCL1 expression was observed in liver metastases. - Conclusion - These data identify molecular PD-L1 features in NEPCA. The predictive role of PD-L1 status and tumor-infiltrating lymphocytes in NEPCA remains to be established. | ||
| 534 | |c 2018 | ||
| 650 | 4 | |a Checkpoint inhibitors | |
| 650 | 4 | |a Immunotherapy | |
| 650 | 4 | |a Neuroendocrine prostate cancer | |
| 650 | 4 | |a Small-cell prostate cancer | |
| 650 | 4 | |a TIL | |
| 700 | 1 | |a Hartmann, Sarah |d 1988- |e VerfasserIn |0 (DE-588)118272812X |0 (DE-627)1662886888 |4 aut | |
| 700 | 1 | |a Nitschke, Katja |d 1984- |e VerfasserIn |0 (DE-588)1075770823 |0 (DE-627)833830651 |0 (DE-576)444648046 |4 aut | |
| 700 | 1 | |a Worst, Thomas |d 1985- |e VerfasserIn |0 (DE-588)1028335679 |0 (DE-627)73058500X |0 (DE-576)375827501 |4 aut | |
| 700 | 1 | |a Nuhn, Philipp |d 1981- |e VerfasserIn |0 (DE-588)136112951 |0 (DE-627)694090808 |0 (DE-576)30083909X |4 aut | |
| 700 | 1 | |a Weis, Cleo-Aron Thias |d 1985- |e VerfasserIn |0 (DE-588)1062803752 |0 (DE-627)806961198 |0 (DE-576)42022730X |4 aut | |
| 700 | 1 | |a Erben, Philipp |d 1973- |e VerfasserIn |0 (DE-588)128501014 |0 (DE-627)373920997 |0 (DE-576)297181661 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical genitourinary cancer |d Dallas, Tex. : CIG Media Group, 2005 |g 17(2019), 2, Seite 145-153.e5 |h Online-Ressource |w (DE-627)585792658 |w (DE-600)2466266-5 |w (DE-576)358411122 |x 1938-0682 |7 nnas |a Programmed death ligand 1 (PD-L1) status and tumor-infiltrating lymphocytes in hot spots of primary and liver metastases in prostate cancer with neuroendocrine differentiation |
| 773 | 1 | 8 | |g volume:17 |g year:2019 |g number:2 |g pages:145-153.e5 |g extent:14 |a Programmed death ligand 1 (PD-L1) status and tumor-infiltrating lymphocytes in hot spots of primary and liver metastases in prostate cancer with neuroendocrine differentiation |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.clgc.2018.12.007 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S1558767318305895 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20190405 | ||
| 993 | |a Article | ||
| 994 | |a 2019 | ||
| 998 | |g 128501014 |a Erben, Philipp |m 128501014:Erben, Philipp |d 60000 |d 63100 |e 60000PE128501014 |e 63100PE128501014 |k 0/60000/ |k 1/60000/63100/ |p 9 |y j | ||
| 998 | |g 1062803752 |a Weis, Cleo-Aron Thias |m 1062803752:Weis, Cleo-Aron Thias |d 60000 |d 63400 |e 60000PW1062803752 |e 63400PW1062803752 |k 0/60000/ |k 1/60000/63400/ |p 8 | ||
| 998 | |g 136112951 |a Nuhn, Philipp |m 136112951:Nuhn, Philipp |d 60000 |d 63100 |e 60000PN136112951 |e 63100PN136112951 |k 0/60000/ |k 1/60000/63100/ |p 7 | ||
| 998 | |g 1028335679 |a Worst, Thomas |m 1028335679:Worst, Thomas |d 60000 |d 63100 |e 60000PW1028335679 |e 63100PW1028335679 |k 0/60000/ |k 1/60000/63100/ |p 4 | ||
| 998 | |g 1075770823 |a Nitschke, Katja |m 1075770823:Nitschke, Katja |d 60000 |d 63100 |e 60000PN1075770823 |e 63100PN1075770823 |k 0/60000/ |k 1/60000/63100/ |p 3 | ||
| 998 | |g 118272812X |a Hartmann, Sarah |m 118272812X:Hartmann, Sarah |d 60000 |d 63100 |e 60000PH118272812X |e 63100PH118272812X |k 0/60000/ |k 1/60000/63100/ |p 2 | ||
| 998 | |g 1020494328 |a Hardenberg, Jost von |m 1020494328:Hardenberg, Jost von |d 60000 |d 63100 |e 60000PH1020494328 |e 63100PH1020494328 |k 0/60000/ |k 1/60000/63100/ |p 1 |x j | ||
| 999 | |a KXP-PPN1662886128 |e 3418301576 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"id":{"eki":["1662886128"],"doi":["10.1016/j.clgc.2018.12.007"]},"physDesc":[{"extent":"14 S."}],"note":["Available online 21 December 2018","Gesehen am 22.05.2019"],"relHost":[{"pubHistory":["4.2005/06,3 -"],"part":{"pages":"145-153.e5","extent":"14","issue":"2","text":"17(2019), 2, Seite 145-153.e5","year":"2019","volume":"17"},"language":["eng"],"title":[{"title":"Clinical genitourinary cancer","title_sort":"Clinical genitourinary cancer"}],"note":["Gesehen am 14.04.25"],"id":{"zdb":["2466266-5"],"issn":["1938-0682"],"eki":["585792658"]},"physDesc":[{"extent":"Online-Ressource"}],"disp":"Programmed death ligand 1 (PD-L1) status and tumor-infiltrating lymphocytes in hot spots of primary and liver metastases in prostate cancer with neuroendocrine differentiationClinical genitourinary cancer","origin":[{"publisher":"CIG Media Group","dateIssuedDisp":"2005-","dateIssuedKey":"2005","publisherPlace":"Dallas, Tex."}],"recId":"585792658","type":{"bibl":"periodical","media":"Online-Ressource"}}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"recId":"1662886128","origin":[{"dateIssuedDisp":"2019","dateIssuedKey":"2019"}],"person":[{"display":"Hardenberg, Jost von","role":"aut","given":"Jost von","family":"Hardenberg"},{"family":"Hartmann","given":"Sarah","role":"aut","display":"Hartmann, Sarah"},{"family":"Nitschke","display":"Nitschke, Katja","given":"Katja","role":"aut"},{"role":"aut","given":"Thomas","display":"Worst, Thomas","family":"Worst"},{"family":"Nuhn","display":"Nuhn, Philipp","role":"aut","given":"Philipp"},{"family":"Weis","display":"Weis, Cleo-Aron Thias","given":"Cleo-Aron Thias","role":"aut"},{"role":"aut","given":"Philipp","display":"Erben, Philipp","family":"Erben"}],"name":{"displayForm":["Jost von Hardenberg, Sarah Hartmann, Katja Nitschke, Thomas Stefan Worst, Saskia Ting, Henning Reis, Philipp Nuhn, Cleo-Aron Weis, Philipp Erben"]},"title":[{"title":"Programmed death ligand 1 (PD-L1) status and tumor-infiltrating lymphocytes in hot spots of primary and liver metastases in prostate cancer with neuroendocrine differentiation","title_sort":"Programmed death ligand 1 (PD-L1) status and tumor-infiltrating lymphocytes in hot spots of primary and liver metastases in prostate cancer with neuroendocrine differentiation"}],"language":["eng"]} | ||
| SRT | |a HARDENBERGPROGRAMMED2019 | ||